Effect of antisense hypoxia-inducible factor 1αon progression, metastasis, and chemosensitivity of pancreatic cancer

Pancreas

Volumn 32, Issue 3, 2006, Pages 297-305

  Chang, Qing ^a   Qin, Renyi ^a   Huang, Tao ^a   Gao, Jun ^a   Feng, Yanping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antisense; BxPc 3; Hypoxia inducible factor 1 ; Pancreatic cancer

Indexed keywords

BETA1 INTEGRIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SURVIVIN; BIRC5 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; DISEASE COURSE; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FAMILY; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL MOTION; COLORIMETRY; DRUG ANTAGONISM; GENE THERAPY; GENETICS; MALE; MOUSE; NUCLEIC ACID PROBE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIGENS, CD29; ANTISENSE ELEMENTS (GENETICS); APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; COLORIMETRY; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33646707041     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200604000-00010     Document Type: Article

References (69)

1. 2 tension. Am J Physiol. 1996;271:C1172-C1180.
2. Kallio PJ, Wilson WJ, O'Brien S, et al. Regulation of the hypoxia-inducible transcription factor 1 alpha by the ubiquitin-proteasome pathway. J Biol Chem. 1999;274:6519-6525.
3. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBOJ. 1998;17:3005-3015.
4. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157:411-421.
5. Kurokawa T, Miyamoto M, Kato K, et al. Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer. 2003;89:1042-1047.
6. Vodermark D, Shibata T, Brown JM. Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia. 2001;3:527-534.
7. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-583.
8. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315-5320.
9. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
10. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001;34:207-212.
11. Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882-883.
12. Chang Q, Liu ZR, Wang DY, et al. Survivin expression induced by doxorubicin in cholangiocarcinoma. World J Gastroenterol. 2004;10:415-418.
13. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071-5074.
14. Lu CD, Altieri DC, Tanigawa N. Expression of novel anti-apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808-1812.
15. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
16. Lee JP, Chang KH, Han JH, et al. Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors. Int J Gynecol Cancer. 2005;15:113-119.
17. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271-278.
18. Sarela AI, Verbeke CS, Ramsdale J, et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86:886-892.
19. Altieri DC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 1999;79:1327-1333.
20. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense nucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805-2809.
21. Schwartz MA. Integrins, oncogenes, and anchorage independence. J Cell Biol. 1997;139:575-578.
22. Banai K, Brady K, McDonald F. A preliminary optical and electron microscopic study of the beta(1) integrin distribution pattern of human osteosarcoma-derived cells. Histochem Cell Biol. 2004;122:75-80.
23. Zou JX, Liu Y, Pasquale EB, et al. Activated SRC oncogene phosphorylates R-ras and suppresses integrin activity. J Biol Chem. 2002;277:1824-1827.
24. Henderson NC, Collis EA, Mackinnon AC, et al. CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation. J Biol Chem. 2004;279:54731-54741.
25. Weaver VM, Petersen OW, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997;137:231-245.
26. Oshita F, Ito H, Ikehara M, et al. Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. Am J Clin Oncol. 2004;27:425-428.
27. Shintani Y, Higashiyama S, Ohta M, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004;64:4190-4196.
28. Yang C, Zeisberg M, Lively JC, et al. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 2003;63:8312-8317.
29. Arao S, Masumoto A, Otsuki M. Beta1 integrins play an essential role in adhesion and invasion of pancreatic carcinoma cells. Pancreas. 2000;20:129-137.
30. Bourguignon LY, Zhu H, Shao L, et al. CD44 interaction with Tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem. 2000;275:1829-1838.
31. Luparello C, Sirchia R, Pupello D. PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression. J Cell Sci. 2003;116:2421-2430.
32. Li DQ, Wang ZB, Bai J, et al. Effects of mifepristone on invasive and metastatic potential of human gastric adenocarcinoma cell line MKN-45 in vitro and in vivo. World J Gastroenterol. 2004;10:1726-1729.
33. Hou M, Tan L, Wang X, et al. Antisense Tiam1 down-regulates the invasiveness of 95D cells in vitro. Acta Biochim Biophys Sin. 2004;36:537-540.
34. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1á renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001;61:6548-6554.
35. Shibaji T, Nagao M, Ikeda N, et al. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 2003;23:4721-4727.
36. Buchler P, Reber HA, Buchler M, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2003;26:56-64.
37. Buchler P, Reber HA, Buchler MW, et al. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer. 2004;100:201-210.
38. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13:139-168.
39. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 1987;5:313-341.
40. Duffy JP, Eibl G, Reber HA, et al. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer. 2003;2:12.
41. Kitada T, Seki S, Sakaguchi H, et al. Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma. Histopathology. 2003;43:550-555.
42. Hanze J, Eul BG, Savai R, et al. RNA interference for HIF-1alpha inhibits its downstream signalling and affects cellular proliferation. Biochem Biophys Res Commun. 2003;312:571-577.
43. Sun X, Kanwar JR, Leung E, et al. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 2001;8:638-645.
44. Chen J, Zhao S, Nakada K, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol. 2003;162:1283-1291.
45. Blasco F, Penuelas S, Cascallo M, et al. Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy. Oncology. 2004;67:277-290.
46. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat. 2002;5:65-72.
47. Altieri D. Blocking survivin to kill cancer cells. Methods Mol Biol. 2003;223:533-542.
48. Tu SP, Cui JT, Liston P, et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology. 2005;128:361-375.
49. Xiang R, Mizutani N, Luo Y, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005;65:553-561.
50. Yamamoto T, Manome Y, Nakamura M, et al. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer. 2002;38:2316-2324.
51. Chen T, Tian FZ, Cai ZH, et al. The signal transduction pathway related to hepatocellular carcinoma apoptosis induced by survivin antisense oligonucleotide. Chin J Med. 2003;83:425-429.
52. Penuelas S, Noe V, Ciudad CJ. Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J. 2005;272:696-710.
53. Asanuma K, Moriai R, Yajima T, et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res. 2000;91:1204-1209.
54. Asanuma K, Kobayashi D, Furuya D, et al. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res. 2002;93:1057-1062.
55. Rodel C, Haas J, Groth A, et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys. 2003;55:1341-1347.
56. Pennati M, Binda M, Colella G, et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol. 2003;120:648-654.
57. Wei HY, Chen LB, Wang CY. Correlation of mRNA expression of hypoxia inducible factor-1alpha to biological features of pancreatic cancer. Ai Zheng. 2005;24:184-188.
58. Zhong H, Agani F, Baccala AA, et al. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998;58:5280-5284.
59. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88:2606-2618.
60. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93:309-314.
61. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000;60:4693-4696.
62. Burri P, Djonov V, Aebersold DM, et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:494-501.
63. Volm M, Rittgen W. Cellular predictive factors for the drug response of lung cancer. Anticancer Res. 2000;20:3449-3458.
64. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53:1192-1202.
65. Birner P, Gatterbauer B, Oberhuber G, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer. 2001;92:165-171.
66. Bottger TC, Maschek H, Lobo M, et al. Prognostic value of immunohistochemical expression of beta-1 integrin in pancreatic carcinoma. Oncology. 1999;56:308-313.
67. 1-integrin via ERK 1/2 and p38 MAP kinase in human vascular smooth muscle cells. Biochem Biophys Res Commun. 2002;296:890-896.
68. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 2001;20:4995-5004.
69. Berry MG, Gui GP, Wells CA, et al. Integrin expression and survival in human breast cancer. Eur J Surg Oncol. 2004;30:484-489.